Botulinum Toxin and Nerve Block Tested Together for Chronic Migraine
Tests botulinum toxin with a nerve block in adults with chronic migraine headaches.
Key facts
- Who runs it
- Beni-Suef University
- Where
- Al Fayyum, EgyptSee the site
- Trial code
- Registry title
- Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
- Status
- Not yet recruiting
- People taking part
- 90 people, planned
- Started
- Apr 2026
- Expected to end
- Dec 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- OnabotulinumtoxinA
- Greater Occipital Nerve Block (GONB)
- Record updated
- 17 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic migraine. It tests botulinum toxin (OnabotulinumtoxinA) injections together with a greater occipital nerve block, compared with a single treatment.
- Age
- Older than 18 years
- Sex
- Women and men can join
- Disease stage
- Chronic migraine: headache on 15 or more days per month for more than three months, with at least 8 days per month showing migraine features
- Earlier treatment
- Must have been on a stable migraine preventive treatment for at least two months. Cannot have had BoNT-A or a greater occipital nerve block for headache in the previous 3 months.
Main reasons for not taking part
- Known allergy to BoNT-A or local anesthetics
- Neck anatomy problems that make the injections hard or unsafe
- Neuromuscular junction disorders such as myasthenia gravis
- Bleeding disorders or blood thinner treatment that rules out a nerve block
- Pregnancy
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3): headache occurring on ≥15 days per month for more than three months, with at least 8 days per month exhibiting migraine features. (International Headache Society, 2013)
- Age > 18 years
- Stable preventive migraine regimen for at least two months prior to recruitment
Who cannot take part
- Prior treatment with BoNT-A or GONB for headache within the previous 3 months
- Known hypersensitivity to BoNT-A or local anesthetics
- Neuromuscular junction disorders (e.g., myasthenia gravis)
- Coagulation disorders or anticoagulant therapy that contraindicates nerve block
- Significant psychiatric comorbidity that would impair proper pre and post treatment assessment
- Co-morbid other
- Cervical anatomical abnormalities that hinder proper localization of injection sites or compromise the safety of the procedure
- Pregnancy
Where in Egypt
- Beni-Suef University HospitalAl Fayyum, EgyptContact: Rakia Mohamed Basiouny, neurology residentNot yet recruiting
About the trial
What the trial wants to find out
Chronic migraine is a debilitating neurological disorder that significantly affects patients' daily functioning, mental health, and quality of life. Management typically includes acute and preventive treatments, but effectiveness can be limited due to medication overuse or delayed onset of action. OnabotulinumtoxinA injections provide proven long-term preventive benefits, while Greater Occipital Nerve (GON) block offers rapid but short-term relief. Although both treatments are used individually, evidence on the combined effect is limited. This randomized controlled trial aims to evaluate the efficacy and safety of combining OnabotulinumtoxinA injections with GON block, assessing improvements in headache frequency, severity, and patient quality of life compared to single therapy.
The 3 groups in the trial
- Arm 1: BoNT-A + GONBTreatment being tested
Treatment: OnabotulinumtoxinA and Greater Occipital Nerve Block (GONB)
- Arm 2: BoNT-A aloneTreatment being tested
OnabotulinumtoxinA will be injected intramuscularly at standard PREEMPT injection sites for chronic migraine prophylaxis. Total dose per session: 155 units distributed across 31 sites.
Treatment: OnabotulinumtoxinA
- Arm 3: GONB aloneTreatment being tested
Injection of local anesthetic (2% lidocaine, 1-2 mL per side) around the greater occipital nerve at the occipital region. Procedure performed by trained neurologist.
Treatment: Greater Occipital Nerve Block (GONB)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
- Plain-language title
- Botulinum Toxin and Nerve Block Tested Together for Chronic MigraineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 April 2026